A boost for biosimilars payments unveiled by CMS 

CMS announced Monday that it had started to implement a temporary reimbursement boost for biosimilars that is mandated in the Inflation Reduction Act.

Under the law, the add-on payment for biosimilars administered in physician offices, hospital outpatient departments, and ambulatory surgical centers will be 8% of the average sales price (ASP) or the reference drug. Prior to enactment of the IRA, the add-on payment for biosimilars was 6% of the reference product’s ASP. ...